Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Eliem Therapeutics, Inc. | COO & CFO | Stock Option (Right to Buy) | 170K | Oct 31, 2022 | Direct | ||
Neoleukin Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25K | Jun 8, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
NLTX | Neoleukin Therapeutics, Inc. | Jun 8, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
ELYM | Eliem Therapeutics, Inc. | Oct 31, 2022 | 1 | $0 | 4 | Nov 2, 2022 | COO & CFO |
NLTX | Neoleukin Therapeutics, Inc. | May 12, 2022 | 1 | $0 | 4 | May 16, 2022 | Director |
ELYM | Eliem Therapeutics, Inc. | Jan 27, 2022 | 1 | $0 | 4 | Jan 31, 2022 | COO & CFO |
ELYM | Eliem Therapeutics, Inc. | Aug 9, 2021 | 0 | $0 | 3 | Aug 9, 2021 | COO & CFO |